Leave Your Message

Daim Ntawv Qhia Tag Nrho ntawm Kev Kho Mob Leukemia Groundbreaking

CAR-T Therapy, luv luv rau Chimeric Antigen Receptor T-Cell Immunotherapy, yog ib txoj kev kho noob caj noob ces uas cuam tshuam txog kev hloov kho cov noob caj noob ces tus neeg mob tus kheej T hlwb rau lub hom phiaj thiab rhuav tshem cov qog nqaij hlav cancer. Tsis zoo li cov tshuaj ib txwm siv, CAR-T txoj kev kho yog haum rau txhua tus neeg mob thiab yuav tsum tau sau cov T hlwb los ntawm tus neeg mob cov ntshav ua ntej rov ua rau lawv rov qab mus rau hauv lub cev tom qab kev tshuaj ntsuam genetic engineering.

    Indications ntawm CAR-T

    B-cell mob lymphoblastic leukemia

    Ntau myeloma

    Chronic lymphocytic leukemia

    Tsis yog Hodgkin lymphoma

    Diffuse loj B-cell lymphoma

    SLE (Systemic Lupus Erythematosus)

    Myasthenia gravis

    Lwm yam kab mob autoimmune

    Kev ua tau zoo ntawm CAR-T kev kho mob

    Indications rau CD19+20CAR-T:Cov neeg mob uas muaj B-cell tsis yog Hodgkin's lymphoma

    Ib hlis CR tus nqi

    Ib hlis PR tus nqi

    Ib hlis LOS YOG tus nqi

    CRS≥3

    CRES ≥ 3

    71.95% (59/82)

    25.6 (21/82)

    97.55 (80/82)

    12.19% (10/82)

    0

    Indications rau CD19+22CAR-T:Kev kho mob ntawm CD19 relapsed thiab refractory mob B-lymphocytic leukemia cov neeg mob

    Ib hlis CR tus nqi

    Ib hlis PR tus nqi

    Ib hlis LOS YOG tus nqi

    CRS≥3

    CRES ≥ 3

    92.1% (35/38)

    7.9% (3/38)

    100% (38/38)

    15.79% (6/38)

    0

    Indications rau BCMACAR-T:Kev kho mob ntawm relapsed thiab refractory ntau myeloma

    Ib hlis CR tus nqi

    Ib hlis PR tus nqi

    Ib hlis LOS YOG tus nqi

    CRS≥3

    CRES ≥ 3

    72.41% (21/29)

    27.59% (8/29)

    100% (29/29)

    6.9% (2/29)

    0

    CAR-T KEV PAB CUAM (2)tch

    Peb Qhov Zoo

     Kev kho tus kheej: Txhua txoj kev kho CAR-T raug kho rau tus neeg mob, kom ntseeg tau cov txiaj ntsig kev kho mob zoo heev.

     Muaj ntau hom phiaj kev xaiv: Nrog rau ntau hom phiaj antigens, suav nrog CD7, CD19, CD20, CD22, thiab BCMA, peb cov khoom CAR-T muaj ntau yam tsis sib xws hauv kev kho ntau yam hematological malignancies thiab kab mob autoimmune.

     Pov thawj Clinical Success: Peb cov kev kho mob CAR-T tau pom tias muaj txiaj ntsig tshwj xeeb thoob plaws ntau qhov chaw kho mob, nrog rau cov txiaj ntsig zoo thiab kev nyab xeeb, txhawb nqa peb txoj haujlwm ua tus thawj coj hauv kev tiv thaiv kab mob.

     Tus nqi-zoo: Peb muab kev sib tw nrog cov kev kho mob zoo tshaj ntawm tus nqi siv tau ntau dua piv rau lwm cov khoom siv CAR-T hauv khw.

     Txiav-Edge Technology: Siv cov kev nce qib tshiab kawg hauv kev tsim noob caj noob ces, peb cov kev kho mob CAR-T embody lub neej yav tom ntej ntawm kev mob qog noj ntshav thiab kev kho kab mob autoimmune.

     Kev Pabcuam Kws Kho Mob: Peb pab pawg kws kho mob thiab cov kws tshawb fawb tau paub txog muab kev saib xyuas zoo los ntawm kev sab laj thawj zaug los ntawm kev tswj hwm kev kho mob thiab kev soj ntsuam.

    CAR-T hlwb tam sim no tau lees paub dav dav rau lawv cov kev ua tau zoo hauv cov neeg mob uas tsis tau teb rau cov kev kho mob ib txwm muaj xws li tshuaj kho mob lossis hloov pob txha pob txha. Lub zej zog kho mob thoob ntiaj teb lees paub qhov muaj peev xwm ntawm CAR-T txoj kev kho hauv kev hloov pauv cov txiaj ntsig ntawm tus neeg mob.

    piav 2

    Fill out my online form.